Processa Pharmaceuticals (PCSA) said Tuesday it has entered into a binding agreement granting Intact Therapeutics an exclusive option to license PCS12852, a potential treatment for gastroparesis and other gastrointestinal motility disorders.
The agreement could provide Processa with a $2.5 million option exercise fee, up to $20 million in development and regulatory milestones, and over $432.5 million in commercial milestones, the pharmaceutical company said, adding that it will also receive a double-digit royalty on global net sales, excluding South Korea, and a 3.5% equity stake in Intact.
Processa said it must share 60% of any cash proceeds, excluding the equity stake, with its licensor, per the existing agreement.
PCS12852 showed promising safety and efficacy in a phase 2a trial for diabetic gastroparesis, the company said.
The exclusive license will be effective upon completion of definitive agreements and other closing conditions, it added.
Shares of Processa were up 208% in recent Tuesday trading.
Price: 0.69, Change: +0.47, Percent Change: +208.00
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.